A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

摘要: // Richard E. Kast 1 , John A. Boockvar 2 Ansgar Bruning 3 Francesco Cappello 4 Wen-Wei Chang 5 Boris Cvek 6 Q. Ping Dou 7 Alfonso Duenas-Gonzalez 8 Thomas Efferth 9 Daniele Focosi 10 Seyed H. Ghaffari 11 Georg Karpel-Massler 12 Kirsi Ketola 13 Alireza Khoshnevisan 14 Daniel Keizman 15 Nicolas Magne 16 Christine Marosi 17 Kerrie McDonald 18 Miguel Munoz 19 Ameya Paranjpe 20 Mohammad Pourgholami Iacopo Sardi 21 Avishay Sella 22 Kalkunte S. Srivenugopal Marco Tuccori Weiguang Wang 23 Christian R. Wirtz Marc-Eric Halatsch IIAIGC Headquarters, Dean of Studies, Burlington, VT, USA Weill Cornell Medical College, NY, University Munchen, Germany Palermo, Italy Chung Shan Hospital, Taichung, Taiwan Palacky University, Olomouc, Czech Republic Wayne State Detroit, Instituto de Investigaciones Biomedicas UNAM, Nacional Cancerologia, Mexico City, Johannes Gutenberg Mainz, Pisa, Tehran Sciences, Tehran, Iran Ulm, British Columbia, Vancouver, Canada Shariati Oncology Department, Meir Center, Tel Aviv Israel Institut Cancerologie Lucien Neuwirth, Saint-Priest en Jarez, France Vienna, Wein, Austria New South Wales, Sydney, Australia Virgen del Rocio Sevilla, Spain Texas Tech Health Sciences Amarillo, Meyer Children’s Firenze, Assaf Harofeh Zerifin, Wolverhampton, UK Correspondence: email: Keywords : angiotensin, aprepitant, artesunate, auranofin, captopril, cytokines, disulfiram, glioblastoma, ketoconazole, nelfinavir, neurokinin, sertraline, temozolomide Received April 7, 2013 Accepted 11, Published 13, Abstract To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on combination drugs not traditionally thought as cytotoxic chemotherapy agents but that have robust history being well-tolerated and are already marketed used for other non-cancer indications. Focus was adding which met these criteria: a) were pharmacologically well characterized, b) had low likelihood to patient side effect burden, c) evidence interfering with recognized, well-characterized growth promoting element d) coordinated, an ensemble reasonable concerted activity against key biological features growth. We found nine meeting criteria propose them continuous dose temozolomide, currently accepted relapsed patients disease after primary the Stupp Protocol. The adjuvant drug regimen, Coordinated Undermining Survival Paths, CUSP9, then copper gluconate, be added temozolomide. discuss each turn specific rationale use- how is expected retard undermine glioblastoma’s compensatory mechanisms engaged during treatment. risks pharmacological interactions why believe this mix will increase both quality life overall survival reviewed.